Literature DB >> 7526318

Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein.

Y Legros1, A Meyer, K Ory, T Soussi.   

Abstract

Human p53 displays two immunodominant regions localized in the amino and carboxy termini of the protein. Using a truncated p53 (residues 66 to 361), we selected eight new monoclonal antibodies directed to the central part of the protein. We identified the epitopes recognized by seven out of eight antibodies with a set of overlapping peptides. One of these antibodies had an epitope similar to PAb240, whereas the others recognized novel and diverse antigenic determinants. Using a series of 19 p53 mutants, we show that the behavior of several of the new monoclonal antibodies is similar to that of PAb240 despite their various epitope localizations. This suggests that different mutations in the p53 protein induce an overall conformational change that can be detected by various monoclonal antibodies directed toward the central part of the protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526318

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Unexpected frameshifts from gene to expressed protein in a phage-displayed peptide library.

Authors:  J Cárcamo; M W Ravera; R Brissette; O Dedova; J R Beasley; A Alam-Moghé; C Wan; A Blume; W Mandecki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

2.  p53 DNA binding can be modulated by factors that alter the conformational equilibrium.

Authors:  K G McLure; P W Lee
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

3.  Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability.

Authors:  M H Kubbutat; K H Vousden
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

4.  A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.

Authors:  C Gaiddon; M Lokshin; J Ahn; T Zhang; C Prives
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

5.  Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins.

Authors:  P J Moos; K Edes; F A Fitzpatrick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

6.  Hot-spot mutants of p53 core domain evince characteristic local structural changes.

Authors:  K B Wong; B S DeDecker; S M Freund; M R Proctor; M Bycroft; A R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

7.  Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C.

Authors:  J Raedle; W K Roth; G Oremek; W F Caspary; S Zeuzem
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

8.  Detection of p73 antibodies in patients with various types of cancer: immunological characterization.

Authors:  O Tominaga; K Unsal; G Zalcman; T Soussi
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

9.  Small molecule induced reactivation of mutant p53 in cancer cells.

Authors:  Xiangrui Liu; Rainer Wilcken; Andreas C Joerger; Irina S Chuckowree; Jahangir Amin; John Spencer; Alan R Fersht
Journal:  Nucleic Acids Res       Date:  2013-04-29       Impact factor: 16.971

10.  A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.

Authors:  Alessia Garufi; Daniela Trisciuoglio; Manuela Porru; Carlo Leonetti; Antonella Stoppacciaro; Valerio D'Orazi; Maria Avantaggiati; Alessandra Crispini; Daniela Pucci; Gabriella D'Orazi
Journal:  J Exp Clin Cancer Res       Date:  2013-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.